Gland Pharma’s consolidated net profit increased 47 per cent to ₹317 crore in the first quarter ended June 30, 2026, compared to ₹215 crore in the corresponding quarter of the previous financial year.The total revenue of the Hyderabad-based company increased 20 per cent to ₹1,800 crore in the quarter under review against ₹1,505 crore in the year-ago period.“Our strong start to FY27 reflects the successful execution of our Contract Development and Manufacturing Organisation (CDMO) strategy and the resilience of our B2B business model. Growth was driven by recent product launches from CDMO portfolio and strong customer demand for our diversified product mix,” Srinivas Sadu, Executive Chairman of Gland Pharma, said in a release on Monday.The company would continue to strengthen its growth platform through a robust CDMO pipeline, including investments in differentiated technologies and capacity expansions, he added.Published on August 10, 2026
Gland Pharma net profit rises 47% to ₹317 crore in Q1
Strong performance driven by product launches and robust demand in CDMO segment, signaling a promising outlook for the fiscal year ahead
TL;DRAI
Gland Pharma's Q1 net profit surged 47% to ₹317 crore, revenue +20%, driven by CDMO portfolio. CDMO scaling as a contract outsourcing model informs IT investment in supply-chain systems and infrastructure, as enterprises consolidate manufacturing partnerships.
142 words~1 min read
